ArticleSaudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case.
Article in Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Case Report: An interesting case of vision and hearing loss revealing CNS recurrence in Philadelphia-positive acute lymphoblastic leukemia.Frontiers in oncology · 2026Article
- Neurological Adverse Events Associated with the Use of Janus Kinase Inhibitors: A Pharmacovigilance Study Based on Vigibase.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Side Effects of Novel Anticancer Drugs on the Posterior Segment of the Eye: A Review of the Literature.Journal of personalized medicine · 2024Review
- Neuro-ophthalmic complications of modern anti-cancer drugs.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Review
- Case report: First report of isolated central nervous system lymphoblastic crisis in a child with chronic myeloid leukemia on dasatinib therapy.Frontiers in oncology · 2023Article
- Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.Leukemia & lymphoma · 2022Article
- Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.American journal of hematology · 2022Article
- Ocular Toxicity of Targeted Anticancer Agents.Drugs · 2021Review
- Optic neuritis associated with sunitinib.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.Journal of immunotherapy and precision oncology · 2021Review
- 14th EUNOS Congress: PORTO, PORTUGAL, 16-19 JUNE 2019.Neuro-ophthalmology (Aeolus Press) · 2019Article
- Vogt-Koyanagi-Harada disease like presentation in patients with chronic myeloid leukemia.American journal of ophthalmology case reports · 2018Article
- Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia.Blood research · 2018Article
- Neurological complications of new chemotherapy agents.Neuro-oncology · 2018Article
- Optic neuropathy in the context of leukemia or lymphoma: diagnostic approach to a neuro-oncologic emergency.Neuro-oncology practice · 2017Review
- Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.Clinical pharmacokinetics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The drug dasatinib is a new therapeutic option for patients with chronic myeloid leukemia (CML) as well as acute lymphocytic lymphoblastic leukemia (ALL). However, the scientific literature has not reached a consensus regarding the types of secondary ophthalmologic effects that this drug may have. In this study, we present the case of a 36-year-old male patient who was treated with dasatinib. Two and a half months later, this patient began to experience progressive visual loss in the superior visual field of both eyes. After ruling out various diagnostic options and performing extensive complementary tests, the suspected diagnosis was compatible with optic neuropathy secondary to dasatinib. The patient partially improved after stopping this medication and receiving oral corticosteroid treatment. Although secondary ophthalmological effects related to dasatinib are practically non-existent, our case is the first to report optic neuropathy secondary to this drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.